On January 06, 2020 Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, reported that its corporate name change from "Atossa Genetics Inc." to "Atossa Therapeutics, Inc." became effective at 12:01 a.m. ET today, January 6, 2020 (Press release, Atossa Genetics, JAN 6, 2020, View Source;utm_medium=twitter [SID1234629125]). The Company’s common stock will continue to trade on the NasdaqCM exchange under the ticker symbol "ATOS."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Over the last several years, we have transitioned the Company’s focus on developing therapies to treat breast cancer, breast density and other breast conditions," said Steve Quay, Ph.D., M.D., president and CEO of Atossa. "Changing our name to Atossa Therapeutics, Inc. more clearly reflects our focus on developing therapies and continues to honor Princess Atossa, the great queen of the Achaemenid Empire, who reigned in the fifth century BCE and who is the earliest recorded woman with breast cancer. She is featured in the The Emperor of All Maladies: A Biography of Cancer, the Pulitzer Prize-winning book by Siddhartha Mukherjee on the history of cancer."